{"id":67776,"date":"2026-06-09T22:24:56","date_gmt":"2026-06-09T14:24:56","guid":{"rendered":"https:\/\/flcube.com\/?p=67776"},"modified":"2026-06-09T22:24:58","modified_gmt":"2026-06-09T14:24:58","slug":"hangzhou-highlightll-pharmaceutical-files-for-hong-kong-ipo-with-seven-candidate-pipeline-targeting-autoimmune-and-neurodegenerative-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67776","title":{"rendered":"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hangzhou Highlightll Pharmaceutical Co., Ltd.<\/strong>, a clinical-stage biopharmaceutical company founded in 2017, has filed a prospectus with the <strong>Hong Kong Stock Exchange<\/strong> seeking a public listing to advance its pipeline of seven internally discovered small-molecule drug candidates targeting autoimmune and neurodegenerative diseases.<\/p>\n\n\n\n<h2 id=\"h-company-profile\" class=\"wp-block-heading\">Company Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Founded<\/strong><\/td><td>2017<\/td><\/tr><tr><td><strong>Headquarters<\/strong><\/td><td>Hangzhou, China<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Autoimmune and inflammatory diseases; neurodegenerative disorders<\/td><\/tr><tr><td><strong>Pipeline Status<\/strong><\/td><td>7 small-molecule candidates (4 clinical-stage, 3 preclinical)<\/td><\/tr><tr><td><strong>Listing Venue<\/strong><\/td><td>Hong Kong Stock Exchange (application filed)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-autoimmune-disease-pipeline\" class=\"wp-block-heading\">Autoimmune Disease Pipeline<\/h2>\n\n\n\n<h3 id=\"h-clinical-stage-candidates\" class=\"wp-block-heading\">Clinical-Stage Candidates<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Candidate<\/th><th>Mechanism<\/th><th>Indication<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>TLL-018<\/strong><\/td><td>Selective TYK2\/JAK1 inhibitor<\/td><td>Chronic Spontaneous Urticaria (CSU)<\/td><td>Phase III (China)<\/td><\/tr><tr><td><strong>TLL-018<\/strong><\/td><td>Selective TYK2\/JAK1 inhibitor<\/td><td>Rheumatoid Arthritis (RA)<\/td><td>Phase III (China)<\/td><\/tr><tr><td><strong>HL-300<\/strong><\/td><td>Skin-restricted TYK2\/JAK1\/JAK2 inhibitor<\/td><td>Mild-to-Moderate Atopic Dermatitis (AD)<\/td><td>Clinical-stage (topical formulation)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-neurodegenerative-disease-pipeline\" class=\"wp-block-heading\">Neurodegenerative Disease Pipeline<\/h2>\n\n\n\n<h3 id=\"h-clinical-stage-candidates-0\" class=\"wp-block-heading\">Clinical-Stage Candidates<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Candidate<\/th><th>Mechanism<\/th><th>Target Indications<\/th><th>Key Feature<\/th><\/tr><\/thead><tbody><tr><td><strong>TLL-041\/BHV-8000<\/strong><\/td><td>Brain-penetrant, selective TYK2\/JAK1 inhibitor<\/td><td>Parkinson&#8217;s disease, Alzheimer&#8217;s disease<\/td><td>Designed for neuroinflammatory diseases<\/td><\/tr><tr><td><strong>HL-400<\/strong><\/td><td>Brain-penetrant, selective NLRP3 inhibitor<\/td><td>Parkinson&#8217;s disease<\/td><td>Novel inflammasome targeting approach<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-positioning\" class=\"wp-block-heading\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Internal Discovery Engine<\/strong>: All seven candidates discovered through proprietary research platform<\/li>\n\n\n\n<li><strong>Dual Therapeutic Focus<\/strong>: Balanced portfolio spanning high-prevalence autoimmune conditions and high-unmet-need neurodegenerative disorders<\/li>\n\n\n\n<li><strong>Differentiated Kinase Inhibition<\/strong>: Selective TYK2\/JAK targeting designed to minimize safety concerns associated with broader JAK inhibition<\/li>\n\n\n\n<li><strong>CNS Penetration Capability<\/strong>: Demonstrated expertise in developing brain-penetrant compounds for neurological indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Market<\/strong>: Global autoimmune therapeutics market projected to reach USD 158 billion by 2030<\/li>\n\n\n\n<li><strong>Neurodegenerative Opportunity<\/strong>: Limited treatment options for Parkinson&#8217;s and Alzheimer&#8217;s create significant commercial potential<\/li>\n\n\n\n<li><strong>TYK2 Inhibitor Landscape<\/strong>: Emerging class with demonstrated efficacy and improved safety profile versus pan-JAK inhibitors<\/li>\n\n\n\n<li><strong>Hong Kong Biotech Listings<\/strong>: Continued investor appetite for innovative Chinese biopharmaceutical companies with global potential<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding corporate development, pipeline advancement, regulatory pathways, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and capital market conditions affecting biotechnology IPOs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26060802150_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26060802150_c.\"><\/object><a id=\"wp-block-file--media-362820c9-6f20-40a6-8986-bb2e865744b8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26060802150_c.pdf\">sehk26060802150_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26060802150_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-362820c9-6f20-40a6-8986-bb2e865744b8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3037,72],"class_list":["post-67776","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-highlightll-pharmaceutical","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a prospectus with the Hong Kong Stock Exchange seeking a public listing to advance its pipeline of seven internally discovered small-molecule drug candidates targeting autoimmune and neurodegenerative diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67776\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases\" \/>\n<meta property=\"og:description\" content=\"Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a prospectus with the Hong Kong Stock Exchange seeking a public listing to advance its pipeline of seven internally discovered small-molecule drug candidates targeting autoimmune and neurodegenerative diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67776\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T14:24:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T14:24:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67776#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67776\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases\",\"datePublished\":\"2026-06-09T14:24:56+00:00\",\"dateModified\":\"2026-06-09T14:24:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67776\"},\"wordCount\":333,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Highlightll Pharmaceutical\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67776#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67776\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67776\",\"name\":\"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T14:24:56+00:00\",\"dateModified\":\"2026-06-09T14:24:58+00:00\",\"description\":\"Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a prospectus with the Hong Kong Stock Exchange seeking a public listing to advance its pipeline of seven internally discovered small-molecule drug candidates targeting autoimmune and neurodegenerative diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67776#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67776\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67776#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a prospectus with the Hong Kong Stock Exchange seeking a public listing to advance its pipeline of seven internally discovered small-molecule drug candidates targeting autoimmune and neurodegenerative diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67776","og_locale":"en_US","og_type":"article","og_title":"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases","og_description":"Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a prospectus with the Hong Kong Stock Exchange seeking a public listing to advance its pipeline of seven internally discovered small-molecule drug candidates targeting autoimmune and neurodegenerative diseases.","og_url":"https:\/\/flcube.com\/?p=67776","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T14:24:56+00:00","article_modified_time":"2026-06-09T14:24:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67776#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67776"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases","datePublished":"2026-06-09T14:24:56+00:00","dateModified":"2026-06-09T14:24:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67776"},"wordCount":333,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Highlightll Pharmaceutical","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67776#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67776","url":"https:\/\/flcube.com\/?p=67776","name":"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T14:24:56+00:00","dateModified":"2026-06-09T14:24:58+00:00","description":"Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a prospectus with the Hong Kong Stock Exchange seeking a public listing to advance its pipeline of seven internally discovered small-molecule drug candidates targeting autoimmune and neurodegenerative diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67776#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67776"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67776#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67776"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67776\/revisions"}],"predecessor-version":[{"id":67779,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67776\/revisions\/67779"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}